Detalles de la búsqueda
1.
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
Br J Cancer
; 120(3): 286-293, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30585255
2.
First-in-human trial of the PI3Kß-selective inhibitor SAR260301 in patients with advanced solid tumors.
Cancer
; 124(2): 315-324, 2018 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28976556
3.
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFß) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Clin Transl Sci
; 17(2): e13736, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38362837
4.
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
Lung Cancer
; 184: 107356, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37660479
5.
Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography.
Invest Radiol
; 43(2): 100-11, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18197062
6.
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
Clin Cancer Res
; 18(19): 5314-28, 2012 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22825584
7.
A secreted anti-activator, OspD1, and its chaperone, Spa15, are involved in the control of transcription by the type III secretion apparatus activity in Shigella flexneri.
Mol Microbiol
; 56(6): 1627-35, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15916611
8.
Regulation of transcription by the activity of the Shigella flexneri type III secretion apparatus.
Mol Microbiol
; 43(6): 1543-53, 2002 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-11971264
Resultados
1 -
8
de 8
1
Próxima >
>>